{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:19:11Z","timestamp":1784740751126,"version":"3.55.0"},"reference-count":19,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To better characterize thyroid hormone insufficiency in patients exposed to mitotane.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed medical records of patients from 2 academic centers in Montreal (Canada) and Toulouse (France) with exposure to mitotane therapy for adrenocortical cancer between 1995 and 2020. We analyzed the thyroid function parameters during and after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In our cohort of 83 patients, 17 were excluded because of preexisting primary hypothyroidism or drug-induced hypothyroidism. During follow-up, 3\/66 patients maintained a normal thyroid function and 63\/66 developed central hypothyroidism. Among those 63 patients, 56 presented with an inappropriately normal or low TSH and 7 with a mildly elevated TSH. The onset of hypothyroidism was: &amp;lt;3 months in 33.3%, 3 to 6 months in 19.1%, 6 to 9 months in 14.3%, and 9 to 12 months in 9.5%. At least 14.3% of cases occurred after 12 months of exposure, and 6 patients had an undetermined time of occurrence. Over time, 27 patients stopped mitotane and partial (42.3%) or complete (23.1%) recovery from hypothyroidism was observed, mainly in the first 2 years after mitotane discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Mitotane therapy is frequently associated with new onset of central hypothyroidism with a prevalence of 95.5%. Most cases occurred in the first year of treatment. Partial or full recovery of thyroid function occurs in 65.4% of cases. This study supports the importance of systematic monitoring of TSH and free T4 levels during and following discontinuation of mitotane therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad115","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T16:05:06Z","timestamp":1677686706000},"page":"2336-2342","source":"Crossref","is-referenced-by-count":9,"title":["Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-1247","authenticated-orcid":false,"given":"Jonathan","family":"Poirier","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Godemel","sequence":"additional","affiliation":[{"name":"Service d'Endocrinologie, Maladies m\u00e9taboliques et Nutrition, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, Centre Hospitalo-Universitaire de Toulouse , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-662X","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Mourot","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-448X","authenticated-orcid":false,"given":"Solange","family":"Grunenwald","sequence":"additional","affiliation":[{"name":"Service d'Endocrinologie, Maladies m\u00e9taboliques et Nutrition, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, Centre Hospitalo-Universitaire de Toulouse , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J","family":"Olney","sequence":"additional","affiliation":[{"name":"Oncology Division, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Kim","family":"Le","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-2749","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-7582","authenticated-orcid":false,"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[{"name":"Service d'Endocrinologie, Maladies m\u00e9taboliques et Nutrition, P\u00f4le Cardio-Vasculaire et M\u00e9tabolique, Centre Hospitalo-Universitaire de Toulouse , 31059 Toulouse Cedex , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-4313","authenticated-orcid":false,"given":"Isabelle","family":"Bourdeau","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Research Center, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM) , Montreal, Quebec, H2X 3E4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"issue":"4","key":"2023081819560593500_dgad115-B1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023081819560593500_dgad115-B2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2023081819560593500_dgad115-B3","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"2023081819560593500_dgad115-B4","doi-asserted-by":"crossref","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","article-title":"Results of the ADIUVO Study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients","volume":"5","author":"Terzolo","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2023081819560593500_dgad115-B5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/1871530319666190809144620","article-title":"Prolonged adrenal insufficiency after discontinuation of mitotane therapy","volume":"20","author":"Muratori","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"2023081819560593500_dgad115-B6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2023081819560593500_dgad115-B7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/en.2009-1404","article-title":"Therapeutic concentrations of mitotane (o, p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model","volume":"151","author":"Zatelli","year":"2010","journal-title":"Endocrinology"},{"issue":"9","key":"2023081819560593500_dgad115-B8","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cancers12092615","article-title":"Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2023081819560593500_dgad115-B9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000491388","article-title":"European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism","volume":"7","author":"Persani","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2023081819560593500_dgad115-B10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.14345","article-title":"Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: a retrospective study in 50 Danish patients","volume":"94","author":"Vikner","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023081819560593500_dgad115-B11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","article-title":"The treatment of adrenocortical carcinoma with o, p'-DDD: prognostic implications of serum level monitoring","volume":"20","author":"van Slooten","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"19","key":"2023081819560593500_dgad115-B12","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.3390\/cancers13195001","article-title":"Metabolic and endocrine toxicities of mitotane: a systematic review","volume":"13","author":"Bianchini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023081819560593500_dgad115-B13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.beem.2009.08.003","article-title":"Drugs that suppress TSH or cause central hypothyroidism","volume":"23","author":"Haugen","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2023081819560593500_dgad115-B14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7326\/0003-4819-94-1-141","article-title":"Mitotane and low thyroxine levels","volume":"94","author":"Sacerdote","year":"1981","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023081819560593500_dgad115-B15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"issue":"12","key":"2023081819560593500_dgad115-B16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/a-1658-3077","article-title":"Sunitinib-induced hypothyroidism and survival in pancreatic neuroendocrine tumors","volume":"53","author":"Mathew","year":"2021","journal-title":"Horm Metab Res"},{"issue":"3","key":"2023081819560593500_dgad115-B17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/cancers12030639","article-title":"Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma","volume":"12","author":"Poirier","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023081819560593500_dgad115-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EO-21-0021","article-title":"Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma","volume":"2","author":"Gagnon","year":"2022","journal-title":"Endocr Oncol"},{"issue":"12","key":"2023081819560593500_dgad115-B19","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad115\/49571082\/dgad115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/2336\/51171986\/dgad115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/2336\/51171986\/dgad115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T20:03:04Z","timestamp":1692388984000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/9\/2336\/7059997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad115","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,2,28]]}}}